NRT 6003
Alternative Names: NRT-6003; Yttrium-90 [90Y]; Yttrium-90 carbon microspheresLatest Information Update: 11 Feb 2026
At a glance
- Originator Chengdu New Radiomedicine Technology
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer
- Preclinical Pancreatic cancer
Most Recent Events
- 10 Jun 2025 Chengdu New Radiomedicine Technology completes the phase I trial in Liver cancer (Inoperable/Unresectable) in China (IV, Injection) (NCT06310590)
- 09 May 2025 Chengdu New Radiomedicine Technology initiates a Phase-III clinical trials in Liver cancer (Inoperable/Unresectable) in China (Intra-arterial) (NCT06900543)
- 03 Apr 2025 Phase-III clinical trials in Liver cancer (Inoperable/Unresectable) in China (Intra-arterial) (NCT06909708)